Skip to main content
. 2016 Jun 27;45(7):709–719. doi: 10.1007/s00249-016-1149-7

Fig. 5.

Fig. 5

Pre-treatment increases apoptosis induction. a MDA-MB435S cells were treated with different concentrations of doxorubicin in combination with scFv62-TRAIL (0.1 μg/ml) for 18 h or pre-treated with doxorubicin for 24 h and then with scFv62-TRAIL (0.1 μg/ml) for 18 h. Afterwards, cells were analyzed with Annexin V staining and flow cytometry. b MDA-MB435S cells were treated with doxorubicin for 24 h and afterwards with scFv62-TRAIL for different time spans in presence (red columns) or absence of doxorubicin (white columns). After 18 h, apoptosis induction was measured using Annexin V staining and flow cytometry (two-way ANOVA, **p < 0.01; ***p < 0.001; ****p < 0.0001)